Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.

CD8-Positive T-Lymphocytes / immunology COVID-19 / immunology COVID-19 Vaccines / chemistry Epitopes, T-Lymphocyte HLA Antigens / immunology Humans SARS-CoV-2 / genetics Spike Glycoprotein, Coronavirus / chemistry
CD8(+) T cells COVID-19 SARS-CoV-2 epitopes protection sarbecovirus vaccine variants

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
19 08 2021
Historique:
received: 09 11 2020
revised: 02 04 2021
accepted: 24 06 2021
pubmed: 16 7 2021
medline: 27 8 2021
entrez: 15 7 2021
Statut: ppublish

Résumé

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that escape convalescent and vaccine-induced antibody responses has renewed focus on the development of broadly protective T-cell-based vaccines. Here, we apply structure-based network analysis and assessments of HLA class I peptide stability to define mutationally constrained CD8

Identifiants

DOI: 10.1016/j.cell.2021.06.029 PMID: 34265281 PMC: PMC8241654
pubmed: 34265281
pii: S0092-8674(21)00797-2
doi: 10.1016/j.cell.2021.06.029
pmc: PMC8241654
mid: NIHMS1720169
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Epitopes, T-Lymphocyte 0
HLA Antigens 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4401-4413.e10

Subventions

Organisme : NIAID NIH HHS
ID : DP2 AI154421
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI149704
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK011794
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests E.J.R. and G.D.G. have filed patent application PCT/US2021/028245.

Références

Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Sci Immunol. 2021 Mar 4;6(57):
pubmed: 33664060
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Science. 2019 May 3;364(6439):438-439
pubmed: 31048479
J Infect. 2021 Apr;82(4):e27-e28
pubmed: 33383088
Cell Rep. 2021 Jul 13;36(2):109378
pubmed: 34260940
J Immunol. 2016 Aug 15;197(4):1517-24
pubmed: 27402703
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Protein Pept Lett. 2002 Oct;9(5):379-85
pubmed: 12370025
J Virol. 2009 Aug;83(15):7641-8
pubmed: 19458000
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
BMC Immunol. 2008 Jan 22;9:1
pubmed: 18211710
Vaccine. 2016 Apr 12;34(17):2008-14
pubmed: 26954467
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569
pubmed: 32319118
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Eur J Immunol. 2012 Jun;42(6):1405-16
pubmed: 22678897
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Immunogenetics. 1999 Nov;50(3-4):201-12
pubmed: 10602880
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
J Pept Sci. 2016 Jan;22(1):4-27
pubmed: 26785684
Science. 2019 May 3;364(6439):480-484
pubmed: 31048489
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Microorganisms. 2021 Jul 20;9(7):
pubmed: 34361977
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
Int J Mol Sci. 2021 Aug 24;22(17):
pubmed: 34502041
J Virol. 2014 Oct;88(19):11034-44
pubmed: 25056892
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
J Chem Phys. 2020 Aug 21;153(7):075101
pubmed: 32828084
J Virol. 2021 Mar 1;:
pubmed: 33649194
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
J Immunol. 1989 May 1;142(9):3320-8
pubmed: 2785140
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
PLoS Comput Biol. 2012;8(3):e1002412
pubmed: 22396638
Bioinformatics. 2021 May 17;37(7):929-936
pubmed: 32818261
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
Viruses. 2020 May 06;12(5):
pubmed: 32384820
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Physiol Genomics. 2003 Feb 06;12(3):221-8
pubmed: 12488511
Int J Pept Protein Res. 1991 Jun;37(6):513-20
pubmed: 1917309

Auteurs

Anusha Nathan (A)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Health Sciences & Technology, Harvard Medical School & Massachusetts Institute of Technology, Boston, MA 02115, USA.

Elizabeth J Rossin (EJ)

The Broad Institute, Cambridge, MA 02142, USA; Harvard Medical School Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA 02114, USA.

Clarety Kaseke (C)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Ryan J Park (RJ)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Harvard Radiation Oncology Program, Boston, MA 02114, USA.

Ashok Khatri (A)

Massachusetts General Hospital Endocrine Division and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.

Dylan Koundakjian (D)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Jonathan M Urbach (JM)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Nishant K Singh (NK)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA.

Arman Bashirova (A)

Basic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD 20892, USA.

Rhoda Tano-Menka (R)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Fernando Senjobe (F)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Virology, Harvard Medical School, Boston, MA 02115, USA.

Michael T Waring (MT)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Alicja Piechocka-Trocha (A)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Wilfredo F Garcia-Beltran (WF)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, MA 02115, USA.

A John Iafrate (AJ)

Department of Pathology, Massachusetts General Hospital, MA 02115, USA.

Vivek Naranbhai (V)

Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.

Mary Carrington (M)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD 20892, USA.

Bruce D Walker (BD)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; The Broad Institute, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Institute for Medical Engineering and Science and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Gaurav D Gaiha (GD)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: ggaiha@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Déterminants antigéniques des lymphocytes T › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Structure-guided T cell vaccine design for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Structure-guided T cell vaccine design for...